ArticleResearch and practice in thrombosis and haemostasis2025
Key residues regulating von Willebrand factor A1/A2 interactions: insights from molecular dynamics simulations and experimental validation.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Von Willebrand factor (VWF), secreted by endothelial cells and megakaryocytes, plays a critical role in hemostasis. Under normal physiological conditions, VWF adopts a globular conformation in which the glycoprotein Ibα-binding site on A1 domain is occluded by the adjacent A2 domain. Studies indicate that exogenous free A2 fragments can improve coagulation function following traumatic brain injury by competitively binding to endogenous VWF-A1, highlighting the therapeutic potential of targeting A1/A2 interaction. Objectives: This study aimed to identify key residues regulating the A1/A2 interaction at the interface. Methods: In this study, we used the HADDOCK platform to obtain the optimal conformation of A1/A2 complex and used molecular dynamics simulations to map key binding sites. We conducted multiscale validation using steered molecular dynamics, biolayer interferometry, and atomic force microscopy. Results: Our results identified 3 pairs of strong interdomain hydrogen bonds at the A1/A2 interface: R1334-E1598, Q1367-V1546, and D1323-R1575. Computational analysis indicated that mutations in both A1_mut (D1323A/R1334A/Q1367A) and A2_mut (V1546A/R1575A/E1598A) reduced the A1/A2-binding affinity and conformational stability. Biolayer interferometry assays confirmed a marked reduction in affinity for A1_mut, while the atomic force microscopy experiment showed only a nonsignificant reduction trend. In contrast, A2_mut significantly disrupted A1/A2 binding in both assays. Conclusion: By integrating computational prediction with experimental validation, we identified residues D1323, R1334, and Q1367 on A1, along with V1546, R1575, and E1598 on A2, as key residues that maintain the A1/A2 interaction. These findings enhance our understanding of the VWF-A1/A2 interaction mechanism and provide novel molecular targets and a theoretical basis for developing targeted therapies for associated disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.